We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NDD

News List

Update on US Regulatory Review of Roxadustat in Anaemia of Chronic Kidney Disease americanpharmaceuticalreview
August 12, 2021
The US FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis dependent (NDD) and dialysis-dependent (DD) adult patients.
Pooled Analyses of the Roxadustat Global Phase III Programme Confirmed Cardiovascular Safety drugs
May 20, 2019
Pooled Analyses of the Roxadustat Global Phase III Programme Confirmed Cardiovascular Safety.
Novo Nordisk and e-therapeutics alliance to focus on type-2 diabetes pharmaceutical-technology
December 12, 2018
Novo Nordisk has entered into research collaboration with UK-based E-therapeutics for the development of new treatment strategies for a specific area of type-2 diabetes.....